drugset / Trial / NCT02939872
Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events
Phase 4
Completed
238 enrolled
CardioVascular Research Foundation
CardioVascular Research Foundation, Korea · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.
Timeline
- Start
- 2017-03-09
- Primary completion
- 2021-05-09
- Completion
- 2024-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | — | — |
| Comparator | Clopidogrel | Small molecule | — | — |